Werfen in the news

Roberta Duarte, currently CPO at Werfen, will return to Maersk as Chief People Officer and join the Executive Leadership Team on November 1, 2026.

Werfen received all three 2026 IMV ServiceTrak™ Clinical Laboratory Awards in Coagulation for best customer satisfaction, system performance, and service, based on independent feedback from laboratory professionals.

Werfen resumed dividend payments of 34 million euros to the Rubiralta family in 2025 after integrating Immucor and meeting debt reduction targets, despite a profit drop due to challenging global and Chinese market conditions.

Werfen has launched a point-of-care blood gas analyzer that uses iQM3 technology to detect hemolysis and reduce diagnostic errors.

The Gem Premier 5000 is a point-of-care blood gas analyzer using self-contained cartridges and real-time automated quality monitoring to simplify diagnostic testing.

The global Laboratory Information System market is experiencing robust growth driven by healthcare digitization and AI analytics, with a projected value of USD 4,028.9 million by 2036.

Werfen reported 2.131 million euros in sales in 2025, a 3.3% organic growth, while investing heavily in R&D and strategic infrastructure despite external challenges affecting EBITDA.

Werfen, a Spanish medical device multinational, reported 2.1 billion euros in sales in 2025, leading the Spanish medtech market with two-thirds of sales from Europe and North America.

Werfen's 2025 sales increased by 3.3% to 2.131 million euros, supported by underlying business strength and geographic diversification, with stable net financial debt and strong EBITDA despite macroeconomic challenges.

Werfen experienced a decrease in revenue and profits, attributed to a challenging Chinese market and unfavorable exchange rates, despite maintaining sales stability and investing in R&D.

Werfen, a specialized diagnostics leader, reported 2.131 million euros in sales for 2025, driven by strong organic growth in key regions and continued investment in R&D.

Werfen closed 2025 with ","131 million euros in sales, a 3.3% increase, supported by strong underlying business and geographic diversification, with EBITDA at 473 million euros.

Werfen, a specialized diagnostics and software company, achieved 2.131 million euros in sales in 2025, a 3.3% increase, despite macroeconomic complexities, while maintaining a stable net financial debt.

Werfen experienced a decrease in revenue and profits in 2025, primarily due to market adjustments in China and unfavorable exchange rates in the United States.

Werfen increased sales to 2,131 M in 2025, driven by strong demand in specialized diagnostics, while maintaining high profitability and investing significantly in R&D and facility expansion.

Werfen achieved 2.131 million euros in sales in 2025, an organic growth of 3.3%, despite global complexities, while investing heavily in R&D and strategic infrastructure.

Werfen reported a 3.3% revenue increase to 2,131 million euros in 2025, driven by global diversification and steady investment in diagnostics.

Werfen's net profit decreased by 15% to 144 million euros and sales by 2.4% to 2.131 billion euros, mainly due to currency effects, macroeconomic context, and industry adjustments in China, while investing a record 190 million euros in R&D.

Werfen's sales increased by 3.3% to 2.131 billion euros in 2025, driven by strong underlying business and geographical diversification, with stable net financial debt.

Werfen's net profit fell by 15% to 144 million euros in 2025 due to tariffs and macroeconomic factors, despite a 3.3% increase in sales.